Universal poor survival in children with medulloblastoma harboring somatic TP53 mutations

Journal of Clinical Oncology

Volumn 28, Issue 8, 2010, Pages 1345-1350

  Tabori, Uri ^a   Baskin, Berivan ^a   Shago, Mary ^a   Alon, Noa ^a   Taylor, Michael D ^a   Ray, Peter N ^a   Bouffet, Eric ^a   Malkin, David ^a   Hawkins, Cynthia ^a  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; PROTEIN P53; TUMOR MARKER;

ARTICLE; CANCER GRADING; CANCER SURVIVAL; CANCER SURVIVOR; CHILD; CONTROLLED STUDY; FOLLOW UP; HUMAN; IMMUNOHISTOCHEMISTRY; INFANT; MAJOR CLINICAL STUDY; MEDULLOBLASTOMA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRESCHOOL CHILD; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; SCHOOL CHILD; SENSITIVITY AND SPECIFICITY; SEQUENCE ANALYSIS; SOMATIC MUTATION; TREATMENT FAILURE; WILD TYPE; ADOLESCENT; CANADA; GENETICS; METABOLISM; MORTALITY; MULTIVARIATE ANALYSIS; MUTATION; NEWBORN; PATHOLOGY; RETROSPECTIVE STUDY; SURVIVAL; TUMOR SUPPRESSOR GENE;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; FOLLOW-UP STUDIES; GENES, P53; HUMANS; IMMUNOHISTOCHEMISTRY; INFANT; INFANT, NEWBORN; MEDULLOBLASTOMA; MULTIVARIATE ANALYSIS; MUTATION; ONTARIO; RECEPTOR, ERBB-2; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; SURVIVAL ANALYSIS; TREATMENT FAILURE; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 77950497158     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2009.23.5952     Document Type: Article

References (33)

1. Korones DN: Treatment of newly diagnosed diffuse brain stem gliomas in children: In search of the holy grail. Expert Rev Anticancer Ther 7:663-674, 2007
2. Packer RJ, Vezina G: Management of and prognosis with medulloblastoma: Therapy at a crossroads. Arch Neurol 65:1419-1424, 2008
3. Grill J, Sainte-Rose C, Jouvet A, et al: Treatment of medulloblastoma with postoperative chemotherapy alone: An SFOP prospective trial in young children. Lancet Oncol 6:573-580, 2005 (Pubitemid 41051935)
4. Rutkowski S, Bode U, Deinlein F, et al: Treatment of early childhood medulloblastoma by postoperative chemotherapy alone. N Engl J Med 352: 978-986, 2005 (Pubitemid 40349500)
5. Gajjar A, Chintagumpala M, Ashley D, et al: Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): Long-term results from a prospective, multicentre trial. Lancet Oncol 7:813-820, 2006 (Pubitemid 44464063)
6. Packer RJ, Gajjar A, Vezina G, et al: Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma. J Clin Oncol 24: 4202-4208, 2006 (Pubitemid 46622300)
7. McManamy CS, Lamont JM, Taylor RE, et al: Morphophenotypic variation predicts clinical behavior in childhood non-desmoplastic medulloblastomas. J Neuropathol Exp Neurol 62:627-632, 2003 (Pubitemid 36682635)
8. McManamy CS, Pears J, Weston CL, et al: Nodule formation and desmoplasia in medulloblastomasdefining the nodular/desmoplastic variant and its biological behavior. Brain Pathol 17:151-164, 2007 (Pubitemid 46466135)
9. Grotzer MA, Janss AJ, Fung K, et al: TrkC expression predicts good clinical outcome in primitive neuroectodermal brain tumors. J Clin Oncol 18:1027-1035, 2000 (Pubitemid 30123779)
10. Ellison DW, Onilude OE, Lindsey JC, et al: Beta-catenin status predicts a favorable outcome in childhood medulloblastoma: The United Kingdom Children's Cancer Study Group Brain Tumour Committee. J Clin Oncol 23:7951-7957, 2005 (Pubitemid 46657395)
11. Pizem J, Cort A, Zadravec-Zaletel L, et al: Survivin is a negative prognostic marker in medulloblastoma. Neuropathol Appl Neurobiol 31:422-428, 2005 (Pubitemid 41059863)
12. Pfister S, Remke M, Benner A, et al: Outcome prediction in pediatric medulloblastoma based on DNA copy-number aberrations of chromosomes 6q and 17q and the MYC and MYCN loci. J Clin Oncol 27:1627-1636, 2009
13. Ray A, Ho M, Ma J, et al: A clinicobiological model predicting survival in medulloblastoma. Clin Cancer Res 10:7613-7620, 2004 (Pubitemid 39557524)
14. Thompson MC, Fuller C, Hogg TL, et al: Genomics identifies medulloblastoma subgroups that are enriched for specific genetic alterations. J Clin Oncol 24:1924-1931, 2006
15. Wetmore C, Eberhart DE, Curran T: Loss of p53 but not ARF accelerates medulloblastoma in mice heterozygous for patched. Cancer Res 61:513-516, 2001 (Pubitemid 32128609)
16. de Bont JM, Packer RJ, Michiels EM, et al: Biological background of pediatric medulloblastoma and ependymoma: A review from a translational research perspective. Neuro Oncol 10:1040-1060, 2008
17. Woodburn RT, Azzarelli B, Montebello JF, et al: Intense p53 staining is a valuable prognostic indicator for poor prognosis in medulloblastoma/central nervous system primitive neuroectodermal tumors. J Neurooncol 52:57-62, 2001 (Pubitemid 32544659)
18. Pollack IF, Finkelstein SD, Woods J, et al: Expression of p53 and prognosis in children with malignant gliomas. N Engl J Med 346:420-427, 2002 (Pubitemid 34437697)
19. Louis DN, Ohgaki H, Wiestler OD, et al: The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114:97-109, 2007
20. Eberhart CG, Kepner JL, Goldthwaite PT, et al: Histopathologic grading of medulloblastomas: A Pediatric Oncology Group study. Cancer 94:552-560, 2002 (Pubitemid 34081387)
21. Shlien A, Tabori U, Marshall CR, et al: Excessive genomic DNA copy number variation in the Li-Fraumeni cancer predisposition syndrome. Proc Natl Acad Sci U S A 105:11264-11269, 2008
22. Adesina AM, Nalbantoglu J, Cavenee WK: p53 gene mutation and mdm2 gene amplification are uncommon in medulloblastoma. Cancer Res 54:5649-5651, 1994
23. Saylors RL 3rd, Sidransky D, Friedman HS, et al: Infrequent p53 gene mutations in medulloblastomas. Cancer Res 51:4721-4723, 1991
24. Frank AJ, Hernan R, Hollander A, et al: The TP53-ARF tumor suppressor pathway is frequently disrupted in large/cell anaplastic medulloblastoma. Brain Res Mol Brain Res 121:137-140, 2004 (Pubitemid 38224178)
25. MacDonald TJ, Brown KM, LaFleur B, et al: Expression profiling of medulloblastoma: PDGFRA and the RAS/MAPK pathway as therapeutic targets for metastatic disease. Nat Genet 29:143-152, 2001 (Pubitemid 32952650)
26. Shu HK, Kim MM, Chen P, et al: The intrinsic radioresistance of glioblastoma-derived cell lines is associated with a failure of p53 to induce p21(BAX) expression. Proc Natl Acad Sci U S A 95:14453-14458, 1998
27. Cancer Genome Atlas Research Network: Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455:1061-1068, 2008
28. Gilbertson R, Wickramasinghe C, Hernan R, et al: Clinical and molecular stratification of disease risk in medulloblastoma. Br J Cancer 85:705-712, 2001 (Pubitemid 32929469)
29. Gilbertson RJ, Pearson AD, Perry RH, et al: Prognostic significance of the c-erbB-2 oncogene product in childhood medulloblastoma. Br J Cancer 71:473-477, 1995
30. Haberler C, Slavc I, Czech T, et al: Histopathological prognostic factors in medulloblastoma: High expression of survivin is related to unfavourable outcome. Eur J Cancer 42:2996-3003, 2006 (Pubitemid 44755258)
31. Herms JW, Behnke J, Bergmann M, et al: Potential prognostic value of C-erbB-2 expression in medulloblastomas in very young children. J Pediatr Hematol Oncol 19:510-515, 1997 (Pubitemid 28099081)
32. Lain S, Hollick JJ, Campbell J, et al: Discovery, in vivo activity, and mechanism of action of a small-molecule p53 activator. Cancer Cell 13:454-463, 2008 (Pubitemid 351609441)
33. Khuri FR, Nemunaitis J, Ganly I, et al: A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat Med 6:879-885, 2000 (Pubitemid 30644745)